SAN FRANCISCO, Aug. 25 Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced the appointment of Lara Longpre to the position of chief operating officer. Ms. Longpre will be responsible for the development of the company's lead product, JX-594, as well as Jennerex's other product candidates in development and will lead the clinical operations and research, manufacturing, regulatory and quality functions. Ms. Longpre has served as a consultant to Jennerex since 2009.
Advertisement
"Lara's extensive experience in developing therapeutics will make her a key member of our executive management team," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "Her systematic and meticulous approach to operations, combined with her demonstrated leadership ability, make Lara the ideal person to direct the development of JX-594 as we move toward late stage clinical trials in advanced liver cancer."
Advertisement
Ms. Longpre brings to Jennerex over 17 years of broad clinical research, operations, and leadership expertise in all stages of clinical development. Prior to Jennerex, Ms. Longpre held the position of senior vice president, clinical and corporate affairs at MedGenesis Therapeutix and held senior positions at PRA International, a global CRO, including vice president of proposals and contracts, vice president of quality and process management, director of global regulatory affairs, and director of operations. She has directly managed several pivotal Phase 3 trials, and has specific expertise in project management, clinical operations, and quality management systems, including achieving ISO 9001:2000 registration and ensuring Sarbanes-Oxley compliance while at an international CRO. Ms. Longpre holds an M.Sc. in Medical Science from Harvard Medical School, an MBA from Queens University, and B.A. from Cornell University.
About Jennerex
Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer--an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib. Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against cancer cells. Jennerex is headquartered in San Francisco and has research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.
SOURCE Jennerex, Inc.
